Login

Sarah Profitt

ORCID: 0000-0002-2705-7512
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5003699173
Research Areas
  • Chronic Lymphocytic Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • HER2/EGFR in Cancer Research
  • Acute Myeloid Leukemia Research
  • Neuroblastoma Research and Treatments

Vanderbilt University Medical Center
 2023-2025

 Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax
OPENALEX - Publications 
Roma Kankaria Joyce Jones Michael Zargari Dylan Wrinn Alexander Hannah Angle and 5 more Chelsie K. Sievers Sarah Profitt Kateryna Fedorov Claudio A. Mosse Somedeb Ball

10.1080/10428194.2024.2416573 article EN Leukemia & lymphoma/Leukemia and lymphoma 2024-10-16
 Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
OPENALEX - Publications 
James B. Collins Benyam Muluneh Sarah Profitt

10.17615/1e86-6t16 article EN cc-by-nc Carolina Digital Repository (University of North Carolina at Chapel Hill) 2024-03-01
 Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
OPENALEX - Publications 
James B. Collins Benyam Muluneh Sarah Profitt

Tyrosine kinase inhibitors (TKIs) are the mainstay of treatment for chronic myeloid leukemia (CML). Patients enrolled in clinical trials investigating safety and efficacy TKIs CML generally younger, have fewer comorbidities, monitored differently than patients treated real world. This narrative literature review summarizes outcomes (complete cytogenetic response, major molecular disease progression) (duration TKI therapy, discontinuation rates, dosage changes, frequently reported adverse...

10.1177/10781552231217694 article EN cc-by-nc Journal of Oncology Pharmacy Practice 2023-12-17
Coming Soon ...